These findings indicate that hyperkalemia due to the addition of esaxerenone to therapy with an ARB or ACE inhibitor can be considered clinically manageable by adjusting the dosage from 1.25 to 5 mg/day. This evidence concerns the gene ACE and Hyperkalemia.